Europe Anti-Depressants Drugs Market Analysis

Europe Anti-Depressants Drugs Market Analysis


$ 3999

Europe's Anti-Depressants drugs market size was valued at $3.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.64% from 2022 to 2030 and will reach $4.48 Bn in 2030. The market is segmented by drug class, indication, route of administration, end-user, distribution channel, and geography. The Europe Anti-Depressants drug market will grow because of the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies. The key market players are GlaxoSmithKline plc (GBR), AstraZeneca (GBR), Mallinckrodt (GBR), Novartis AG and others.

ID: IN10EUPH051 CATEGORY: Pharmaceuticals GEOGRAPHY: Europe AUTHOR: Chandani Patel

Buy Now

Europe Anti-Depressants Drugs Market Executive Summary

Europe's Anti-Depressants drugs market size was valued at $3.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.64% from 2022 to 2030 and will reach $4.48 Bn in 2030. Mental health expenditure in Europe varies across different countries and depends on several factors, including healthcare systems, government policies, and cultural attitudes toward mental health. According to a report by the European Commission, mental health expenditure in the European Union (EU) was estimated to be around $84.75 Bn, accounting for approximately 6.7% of total healthcare expenditure in the region. The highest mental health expenditure per capita was reported in Denmark (€428), followed by the Netherlands ($414.22) and Austria ($365.49). In contrast, some countries reported much lower mental health expenditure per capita, such as Bulgaria ($20.13), Romania ($30.72), and Latvia ($36.02).

Depression disorder is a significant public health issue in Europe, affecting millions of people every year. According to the World Health Organization, the prevalence of depression in Europe is around 6.6%, with higher rates among women and young adults. It is estimated that around 30 mn people in Europe will experience depressive episodes each year. The prevalence varies across different European countries, with some countries reporting higher rates than others. For example, the prevalence of depression in Germany was around 8.2%, while in the United Kingdom, it was around 6.9%. In Italy, the prevalence was lower, at around 4.8%. Another study published in the European

Depression can have a significant impact on an individual's quality of life, as well as their ability to work and socialize. It can also have a negative impact on physical health, increasing the risk of other health problems such as cardiovascular disease and diabetes. The economic burden of depression in Europe is also substantial, with estimates suggesting that it costs the European Union around $180 billion annually in healthcare costs and lost productivity.

Several factors may contribute to the prevalence and incidence of depression in Europe, including genetics, lifestyle factors, and social and economic factors. In recent years, there has been a growing awareness of the importance of mental health and the need for better access to treatment and support for those with depression and other mental health conditions in Europe. The high prevalence of depression in Europe has a significant impact on the anti-depressant drugs market in the region. Anti-depressants are commonly used to treat depression, and the high demand for these drugs in Europe is driven by the large number of people with the condition.

In addition to the high prevalence of depression, other factors that contribute to the growth of the anti-depressant drugs market in Europe include the aging population and the increasing use of generic drugs. However, the market is also impacted by factors such as drug pricing regulations and the availability of alternative treatments, such as psychotherapy. Overall, the high prevalence of depression in Europe continues to drive demand for anti-depressant drugs and is expected to contribute to the growth of the market in the coming years.

europe anti-depressants drugs market

Market Dynamics

Market Growth Drivers Analysis

The antidepressant drugs market in Europe is primarily driven by the increasing prevalence of depression and related mental health disorders. According to the World Health Organization (WHO), depression affects an estimated 25 million people in the European Union, making it the leading cause of disability and morbidity in the region. Additionally, the growing awareness and acceptance of mental health disorders and the increasing demand for effective treatment options are also driving market growth.

Market Restraints

There are several factors that could potentially restrain the growth of the antidepressant drugs market in Europe. One of the key factors is the stringent regulatory framework for drug approvals and the high cost of drug development. The increasing prevalence of side effects associated with these drugs is another factor that could limit market growth. Additionally, the emergence of alternative therapies such as psychotherapy and cognitive-behavioural therapy, which are considered to be safer and more effective in certain cases, could also pose a challenge to the growth of the antidepressant drugs market in Europe.

Competitive Landscape

Key Players

  • GlaxoSmithKline plc (GBR)
  • AstraZeneca (GBR)
  • Mallinckrodt (GBR.)
  • Novartis AG (CHE)
  • Endo Pharmaceuticals plc (GBR)
  • Johnson & Johnson
  • Allergan (now part of AbbVie Inc.)
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Lundbeck
  • Purdue Pharma
  • Takeda Pharmaceutical Company Limited
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Mylan N.V.
  • Novartis AG

Healthcare Policies and Regulatory Landscape

In Europe, the regulation of antidepressant drugs falls under the authority of the European Medicines Agency (EMA). The EMA is responsible for evaluating the safety and efficacy of antidepressant drugs before they are approved for use in the European Union. Before a new antidepressant drug can be approved for use in the EU, it must undergo a rigorous evaluation process that includes clinical trials to test its safety and effectiveness. The EMA reviews all of the data from these trials and considers factors such as the drug's side effects, dosing information, and contraindications.

Once a new antidepressant drug is approved, it is subject to ongoing monitoring by the EMA to ensure its safety and effectiveness over the long term. This includes monitoring for any new safety concerns that may arise and conducting additional studies as needed. In addition to the regulation of new antidepressant drugs, the EMA also oversees the regulation of generic versions of these drugs. Generic versions must demonstrate that they are bioequivalent to the original drug and meet the same safety and efficacy standards.           

In Europe, the reimbursement of antidepressant drugs is determined at the national level by each country's healthcare system. The reimbursement policies may vary from country to country depending on factors such as the type of healthcare system in place, the availability of funds, and the government's priorities. In general, most European countries have some form of reimbursement policy in place for prescription drugs, including antidepressants. These policies typically cover a portion of the cost of the drug, with patients responsible for paying the remaining portion out of pocket. The exact amount of reimbursement can vary depending on the country and the specific antidepressant drug being prescribed.

Some countries may have a fixed co-pay amount for all prescription drugs, while others may use a tiered system based on the cost of the drug or the patient's income level. In some cases, certain types of antidepressant drugs may be fully covered under the reimbursement policy, while others may only be partially covered or not covered at all. This can be due to factors such as the drug's cost, its effectiveness, or the availability of alternative treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Depressants Drugs Market Segmentation

Drug Class

The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.

  • Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
  • Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
  • Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
  • Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
  • Others

Indication

By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.

  • Major Depressive Disorder
  • Anxiety Disorders
  • Attention Deficit Hyperactivity Disorder
  • Others

Route of Administration

Based on the route of administration the market is segmented into:

  • Oral
  • Injectable
  • Others

End-Users

Based on end users the market is segmented into:

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 21 June 2023
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up